Cholera Vaccines Market Synopsis

Cholera Vaccines Market Size is Valued at USD 5.94 Million in 2023, and is Projected to Reach USD 12.73 Million by 2032, Growing at a CAGR of 10% From 2024-2032.

Cholera Vaccines Market refers to the business market in commercial businesses that engaged in the production, sale and administration of vaccines that are used to prevent cholera, a bacterium that causes acute diarrheal disease that results from ingestion of food or water contaminated with cholera bacteria. These vaccines assist these bodies to gain a response to cholera so that there are no new infections especially to those parts most affected with the disease. This report documents types of vaccines and their subcategories, inactivated whole-cell, and live attenuated vaccines for different age groups and population.

• Some of the main industry drivers include increased cholera outbreak experience in various parts of the world especially developing nations. Due to factors including cholera poor sanitation, inadequate and unsafe water, and climate change there is an incline in the cholera related cases hence leading to increased vaccination especially among the government and health organizations involved. The fact that WHO has now recognized the use of cholera vaccines as an essential component of cholera prevention and control also promotes market growth and increases the focus of funding to support vaccination.
• The outcome is also a result of the increasing knowledge on cholera health effects and need for vaccination. On its part, social mobilization and community mobilization activities with the help of international organizations seek to bring about change in the perception of the population towards cholera and the need to get vaccinated against it. Due to awareness of these signs, people living in regions vulnerable to cholera develop a need for cholera vaccines. Further, advancement in multiple technological parameters in creating or developing the vaccines being a better and safer type, is a key driving force for the market as it boosts people’s confidence in the available vaccines.

Cholera Vaccines Market Trend Analysis

The development of combination vaccines that target multiple diseases.

• One trend that seems to be emerging in the Cholera Vaccines Market is the use of single-vial, multi-valent vaccines. Since healthcare workers are searching for better ways to increase rates of vaccinations, concerns with regard to cholera, as well as other diseases commonly present in endemic areas, have elevated interest in combination vaccines. While it strengthens the voice and reach, this trend also helps to present the immunization and the overall health program between a drastically curbing the burden required for the healthcare systems.
• Another trend that has emerged in the recent procurement approach is digitization of health interventions for enhancement of vaccination. Education over populations on cholera vaccination schedules and availability is being undertaken via m-Health technologies such as Mobile Apps & Short Message Service Reminders. They are especially useful in those regions that many citizens remain underserved or do not have appropriate access to adequate healthcare information; hence the promotion of vaccines.

Governments and non-governmental organizations (NGOs) are increasingly investing in health infrastructure.

• The Cholera Vaccines Market has identified several opportunities, with much scope for expansion evident in the developing regions where cholera is still a major concern. Political sentiments and global health institutions such as NGO’s are now putting their capital into various health investments and vaccinations, which are friendly to manufacturers. Regional opportunities are granted to companies which are able to examine the regional legislation and develop cooperation with the local health authorities.
• Moreover, several sectors such as the trend towards personalizable medicine and vaccination strategies are evolving, which create opportunities to companies. Following epidemiologic features in specific regions and the various demographic characteristics of the population, producers may design suitable vaccines that improve the efficiency and efficacy of the vaccination process. Not only is this a strategic way to address specific health needs but reliance on these products creates more trust within communities thereby increasing vaccine compliance.

Cholera Vaccines Market Segment Analysis:

Cholera Vaccines Market Segmented on the basis of product Type, Technology and End User.

By Product Type, Live Attenuated Vaccines segment is expected to dominate the market during the forecast period

• The market of cholera vaccines has presented several different types of products which are mainly classified into inactivated whole cell vaccines, live attenuated vaccines, and others. This is made from inactivated whole cells and is intended to cause a firm immune response without causing the disease. These are normally given in several doses to ensure that immunity to the causal diseases is developed. Another important classification of the vaccines is by using live attenuated bacteria and these have a typical immune response that is like a natural infection but are usually effective with less doses. Other vaccines can be classified as those that are new formulations, or new combinations of known formulations with respect to the activity of multiple pathogens for the purpose of improving the effectiveness of immunization procedures. Cholera prevention strategies facilitated by both types are equally important; each type serves the purpose of a specific target population and health requirements.

By Technology, Conjugate Vaccines segment held the largest share in 2024

• The cholera vaccines market segmentation also considers the technology option of conjugate vaccines, subunit vaccines, and others. Conjugate vaccines attach the polysaccharide antigens from the bacteria to a carrier protein improving the immune response more so in younger children who may not have adequate immune response to polysaccharide-only vaccines. This technology enables one to have better immunity and have a longer a duration of protection. Subunit vaccines, in contrast, have only certain pieces of the bacteria, such as proteins or sugars that will cause an immune response that does not involve live material of the pathogen. These vaccines are believed to have fewer side effects and are preferred in high-risk populations with different health statuses. There are other formally advanced technologies of vaccines, for example, mRNA or DNA that are under development aimed at increasing the effectiveness and safety of vaccines against cholera.

Cholera Vaccines Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• Due to higher incidence-android- of cholera, the Asia-Pacific region led the Cholera Vaccines Market, followed by South Asia, comprising of India, Bangladesh, and Myanmar. Cholera is by far very rampant in these nations due to poor hygiene and scarce water supply sources. For this reason, governments of countries in the region have over the recent past considered vaccination to be a cornerstone of their public health programs, thus creating a corresponding demand for cholera vaccines.
• In addition, the existence of important companies and research centres in the Asia Pacific region further boosts the territory. The stakeholders involved in the creation of these vaccines are trying to provide the right vaccine that fits the regional cholera market and this has boosted the growth of the global market. Same way the involvement of the region with the other global health institutions also help in funding and support to the vaccination controlling Cholera Vaccines Market.

Active Key Players in the Cholera Vaccines Market

• Sanofi Pasteur (France)
• Valneva SE (France)
• GlaxoSmithKline (GSK) (United Kingdom)
• Merck & Co., Inc. (United States)
• The Serum Institute of India Pvt. Ltd. (India)
• Hilleman Laboratories (India)
• NIPRO (Japan)
• PaxVax, Inc. (United States)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Vaxart, Inc. (United States), Other Active Players.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Cholera Vaccines Market by Product Type
 4.1 Cholera Vaccines Market Snapshot and Growth Engine
 4.2 Cholera Vaccines Market Overview
 4.3 Inactivated Whole Cell Vaccines
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Inactivated Whole Cell Vaccines: Geographic Segmentation Analysis
 4.4 Live Attenuated Vaccines
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Live Attenuated Vaccines: Geographic Segmentation Analysis
 4.5 Other Vaccines
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Other Vaccines: Geographic Segmentation Analysis

Chapter 5: Cholera Vaccines Market by Technology
 5.1 Cholera Vaccines Market Snapshot and Growth Engine
 5.2 Cholera Vaccines Market Overview
 5.3 Conjugate Vaccines
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Conjugate Vaccines: Geographic Segmentation Analysis
 5.4 Subunit Vaccines
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Subunit Vaccines: Geographic Segmentation Analysis
 5.5 Others
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Others: Geographic Segmentation Analysis

Chapter 6: Cholera Vaccines Market by End-User
 6.1 Cholera Vaccines Market Snapshot and Growth Engine
 6.2 Cholera Vaccines Market Overview
 6.3 Government
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Government: Geographic Segmentation Analysis
 6.4 Non-Governmental Organizations (NGOs)
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Non-Governmental Organizations (NGOs): Geographic Segmentation Analysis
 6.5 Private Sector
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Private Sector: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Cholera Vaccines Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 SANOFI PASTEUR (FRANCE)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 VALNEVA SE (FRANCE)
 7.4 GLAXOSMITHKLINE (GSK) (UNITED KINGDOM)
 7.5 MERCK & CO INC (UNITED STATES)
 7.6 THE SERUM INSTITUTE OF INDIA PVT LTD (INDIA)
 7.7 HILLEMAN LABORATORIES (INDIA)
 7.8 NIPRO (JAPAN)
 7.9 PAXVAX INC (UNITED STATES)
 7.10 MITSUBISHI TANABE PHARMA CORPORATION (JAPAN)
 7.11 VAXART INC (UNITED STATES)
 7.12 OTHER ACTIVE PLAYERS

Chapter 8: Global Cholera Vaccines Market By Region
 8.1 Overview
 8.2. North America Cholera Vaccines Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Product Type
  8.2.4.1 Inactivated Whole Cell Vaccines
  8.2.4.2 Live Attenuated Vaccines
  8.2.4.3 Other Vaccines
  8.2.5 Historic and Forecasted Market Size By Technology
  8.2.5.1 Conjugate Vaccines
  8.2.5.2 Subunit Vaccines
  8.2.5.3 Others
  8.2.6 Historic and Forecasted Market Size By End-User
  8.2.6.1 Government
  8.2.6.2 Non-Governmental Organizations (NGOs)
  8.2.6.3 Private Sector
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Cholera Vaccines Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Product Type
  8.3.4.1 Inactivated Whole Cell Vaccines
  8.3.4.2 Live Attenuated Vaccines
  8.3.4.3 Other Vaccines
  8.3.5 Historic and Forecasted Market Size By Technology
  8.3.5.1 Conjugate Vaccines
  8.3.5.2 Subunit Vaccines
  8.3.5.3 Others
  8.3.6 Historic and Forecasted Market Size By End-User
  8.3.6.1 Government
  8.3.6.2 Non-Governmental Organizations (NGOs)
  8.3.6.3 Private Sector
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Cholera Vaccines Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Product Type
  8.4.4.1 Inactivated Whole Cell Vaccines
  8.4.4.2 Live Attenuated Vaccines
  8.4.4.3 Other Vaccines
  8.4.5 Historic and Forecasted Market Size By Technology
  8.4.5.1 Conjugate Vaccines
  8.4.5.2 Subunit Vaccines
  8.4.5.3 Others
  8.4.6 Historic and Forecasted Market Size By End-User
  8.4.6.1 Government
  8.4.6.2 Non-Governmental Organizations (NGOs)
  8.4.6.3 Private Sector
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Cholera Vaccines Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Product Type
  8.5.4.1 Inactivated Whole Cell Vaccines
  8.5.4.2 Live Attenuated Vaccines
  8.5.4.3 Other Vaccines
  8.5.5 Historic and Forecasted Market Size By Technology
  8.5.5.1 Conjugate Vaccines
  8.5.5.2 Subunit Vaccines
  8.5.5.3 Others
  8.5.6 Historic and Forecasted Market Size By End-User
  8.5.6.1 Government
  8.5.6.2 Non-Governmental Organizations (NGOs)
  8.5.6.3 Private Sector
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Cholera Vaccines Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Product Type
  8.6.4.1 Inactivated Whole Cell Vaccines
  8.6.4.2 Live Attenuated Vaccines
  8.6.4.3 Other Vaccines
  8.6.5 Historic and Forecasted Market Size By Technology
  8.6.5.1 Conjugate Vaccines
  8.6.5.2 Subunit Vaccines
  8.6.5.3 Others
  8.6.6 Historic and Forecasted Market Size By End-User
  8.6.6.1 Government
  8.6.6.2 Non-Governmental Organizations (NGOs)
  8.6.6.3 Private Sector
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Cholera Vaccines Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Product Type
  8.7.4.1 Inactivated Whole Cell Vaccines
  8.7.4.2 Live Attenuated Vaccines
  8.7.4.3 Other Vaccines
  8.7.5 Historic and Forecasted Market Size By Technology
  8.7.5.1 Conjugate Vaccines
  8.7.5.2 Subunit Vaccines
  8.7.5.3 Others
  8.7.6 Historic and Forecasted Market Size By End-User
  8.7.6.1 Government
  8.7.6.2 Non-Governmental Organizations (NGOs)
  8.7.6.3 Private Sector
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research